Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-15

Study Completion Date

2015-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with Systemic lupus erythematosus (SLE) are known to present an increased risk of osteoporosis and cardiovascular calcification. It has also been suggested that bone remodelling and cardiovascular calcification are regulated by the same mechanisms, but inversely in terms of calcium deposition, as osteoporosis is often associated with cardiovascular calcification. Inflammatory and immune factors have been implicated in these two processes.

The role of the RANKL/OPG system in osteoclast differentiation has been elucidated over the last ten years. RANKL induces differentiation of monocytes-macrophages into osteoclasts, while, inversely, OPG exerts an inhibitory role by inactivating RANKL. Differentiation of smooth muscle cells into osteoblasts in the vessel wall induces calcification, and this phenomenon is counterbalanced by differentiation of monocytes into osteoclasts. Although the role of the RANKL/OPG ratio in the pathogenesis of osteoporosis has now been clearly established, its role in vascular calcification is only hypothetical at the present time.

This study will focus on patients with SLE diagnosed and followed in the Amiens University Hospital Internal Medicine and Nephrology departments

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bone Mineral Density in Patients with Childhood-onset Systemic Lupus Erythematous, in Relation to Disease Clinical Criteria

NCT06586359

Systemic Lupus Erthematosus

NOT_YET_RECRUITING

Predictors of Bone Mineral Density in Lupus Nephritis Activity

NCT06837558

Bone Mineral Density and Lupus Nephritis Activity

NOT_YET_RECRUITING

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.

NCT02891213

Lupus Erythematosus

UNKNOWN

Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients

NCT02922114

Lupus Erythematosus, Systemic

COMPLETED NA

Lupus Arthritis: Muscoloskeletal Ultrasound as Clinical Outcome of Peripheral Blood and Synovial Deep Phenotyping

NCT07102238

Systemic Lupus Erythematosus

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis Lupus Erythematosus, Systemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Systemic lupus erythematosus

RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound

Group Type EXPERIMENTAL

RANKL/OPG ratio

Intervention Type BIOLOGICAL

bone densitometry

Intervention Type DEVICE

fan beam CT scan

Intervention Type DEVICE

Doppler ultrasound

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RANKL/OPG ratio

Intervention Type BIOLOGICAL

bone densitometry

Intervention Type DEVICE

fan beam CT scan

Intervention Type DEVICE

Doppler ultrasound

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women over 18 years old
* suffering from systemic lupus erythematosus.

Exclusion Criteria

underlying diseases that can lead to bone and cardiovascular metabolic disturbances :

* Malignancies such as cancer metastasized
* Autoimmune disease other than LED or of overlap syndrome ( rhupus , MCTD )
* Infection by HIV, hepatitis B and C
* Hepatic Cirrhosis
* Chronic renal failure
* Parathyroid disorders

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No